[Progress in the therapy of children with congenital hemolytic anemias by transfusion of neocyte concentrations. Initial experiences in the separation and transfusion of young erythrocytes, obtained with the cell separator Fenwal CS-3000].
Transfusion-induced hemochromatosis remains a major therapeutic complication in the management of patients with chronic hemolytic anemias. Red cell units harvested with blood cell separators have an average estimated mean cell age of 30 days, compared to 60 days for unfractionated blood. Our initial experience with transfusion of neocytes indicates that the amount of transfused erythrocytes can be reduced on 60 per cent. Further studies must demonstrate the clinical benefit. When combined with modern iron chelator regimens, it may be possible to achieve consistently negative iron balance prior to the onset of hemochromatosis which would allow patients to probably lead a normal life-span.
D000745:Anemia, Hemolytic, Congenital / Q000097:blood / Q000628:therapy*; D001803:Blood Transfusion; D002469:Cell Separation / Q000295:instrumentation*; D002648:Child; D004905:Erythrocyte Aging; D017707:Erythrocyte Transfusion; D006801:Humans; D007501:Iron / Q000097:blood
D007501:Iron
Fortschritte in der Therapie bei Kindern mit angeborenen hämolytischen Anämien durch die Transfusion von Neozytenkonzentraten. Erste Erfahrungen mit der Separation und Transfusion von jungen Erythrozyten gewonnen mit dem Zellseparator Fenwal CS-3000.